Witkiewicz, A. K., Cox, D., & Knudsen, E. S. (2021). Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer.
Chicago-stil citatWitkiewicz, Agnieszka K., Derek Cox, och Erik S. Knudsen. "Correction: CDK4/6 Inhibition Provides a Potent Adjunct to Her2-targeted Therapies in Preclinical Breast Cancer Models." Genes Cancer 2021.
MLA-referensWitkiewicz, Agnieszka K., Derek Cox, och Erik S. Knudsen. "Correction: CDK4/6 Inhibition Provides a Potent Adjunct to Her2-targeted Therapies in Preclinical Breast Cancer Models." Genes Cancer 2021.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.